Gene-Editing Biotechs Pop After Pfizer Partner Scores In Hemophilia AInvestors Business Daily • 04/02/19
Pfizer acquires option to buy Vivet Therapeutics for equivalent of $635.8 millionMarket Watch • 03/20/19